Brief: Pure Biologics Gets 30.1 Mln Zloty Financing For Cancer Drug Development
27/03/2019 09:27
March 27 (Reuters) - Pure Biologics SA PUR1.WA :
* GETS 30.1 MILLION ZLOTY FINANCING FOR CANCER DRUG
DEVELOPMENT
FROM NCBR
* FINANCED PROJECT TO BE REALISED UNDER PUREACTIVATOR NAME,
WITH
ID PB003
Source text for Eikon: ID:nEM4j1Q8ga
Further company coverage: PUR1.WA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48587720920;))
Recent news on Multiqure SA
See all newsBrief: Selvita To Expand Its Operations Through New Biological Drug Business
Brief: Pure Biologics FY Net Loss Widens To 25.6 Mln Zlotys
Brief: Pure Biologics Signs Term Sheet With ACRX Investments On Potential Financing
Brief: Pure Biologics Signs Deal For Subsidy With Poland's Medical Research Agency
Brief: Pure Biologics To Seek Extra Financing For PB003 And PB004 Projects